Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA

KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This multicenter, single-arm, open-label, early exploratory clinical study is designed to evaluate the preliminary safety and efficacy of KSVCBD injection in patients with relapsed or refractory (r/r) multiple myeloma(MM) expressing CD19 and/or BCMA.

NCT Number	NCT07620275
Lead Sponsor	Chinese PLA General Hospital
Conditions	Multiple Myeloma
Enrollment	9 participants
Start Date	2026-06-10
Primary Completion	2028-12-15 (estimated)
Study Completion	2029-03-15 (estimated)
Updated on ClinicalTrials.gov	2026-06-02